Ownership and insider activity for Burning Rock Biotech Limited (BNR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Price
| Price | $14.23 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | CN |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-26 | Han Yusheng | P-Purchase | 24,900 | $199K |
| 2026-06-24 | Han Yusheng | P-Purchase | 250,000 | $2.0M |
| 2026-06-23 | Han Yusheng | P-Purchase | 5,990 | $45K |
| 2026-06-22 | Han Yusheng | P-Purchase | 104,650 | $780K |
| 2026-06-16 | Han Yusheng | P-Purchase | 111,110 | $1000K |
| 2026-06-12 | Han Yusheng | P-Purchase | 210,000 | $1.9M |
| 2026-06-11 | Han Yusheng | P-Purchase | 24,760 | $216K |
| 2026-03-31 | Han Yusheng | P-Purchase | 314,870 | $5.5M |
| 2026-03-18 | DENG FENG | |||
| 2026-03-18 | DENG FENG |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.8M | $93.3M | $94.2M | $1.90B | $1.43B | $905.5M | $615.1M | $519.8M | $481.4M |
| Short-term Investments | $135.2M | $36.8M | $314.0M | $362.1M | $63.8M | 0 | 0 | 0 | 0 |
| Receivables | $41.2M | $35.5M | $89.7M | $110.8M | $161.4M | $170.2M | $149.6M | $173.4M | $182.0M |
| Inventory | $16.8M | $49.1M | $58.1M | $68.0M | $123.2M | $130.3M | $69.0M | $53.8M | $57.0M |
| Total Current Assets | $298.9M | $293.0M | $706.8M | $2.52B | $1.82B | $1.26B | $884.1M | $776.6M | $739.1M |
| Property, Plant & Equipment | $60.7M | $69.6M | $89.3M | $111.5M | $406.4M | $300.0M | $144.2M | $100.3M | $73.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $1.8M | 0 | 0 | 0 |
| Intangible Assets | $516000 | $482000 | $343000 | $3.5M | $5.2M | $161000 | $964000 | $421000 | $284000 |
| Total Assets | $400.3M | $372.7M | $847.6M | $2.66B | $2.28B | $1.59B | $1.04B | $885.3M | $820.9M |
| Accounts Payable | 0 | $16.3M | $12.3M | $35.5M | $63.1M | $50.9M | $18.1M | $33.7M | $40.8M |
| Short-term Debt | $14.9M | $176.3M | $39.5M | $42.1M | $2.4M | 0 | 0 | 0 | $200000 |
| Total Current Liabilities | $78.1M | $284.7M | $164.4M | $241.5M | $372.2M | $411.5M | $263.4M | $266.3M | $247.1M |
| Long-term Debt | $153.8M | $87.6M | $18.3M | 0 | 0 | 0 | 0 | 0 | $1.7M |
| Total Liabilities | $231.8M | $976.1M | $1.74B | $242.0M | $433.3M | $429.1M | $271.6M | $304.5M | $285.3M |
| Retained Earnings | -$379.5M | -$612.0M | -$946.5M | -$1.42B | -$2.23B | -$3.20B | -$3.85B | -$4.20B | -$4.26B |
| Total Equity | $168.5M | -$603.5M | -$891.5M | $2.42B | $1.85B | $1.16B | $768.4M | $580.8M | $535.6M |
| Total Debt | $168.7M | $272.3M | $67.5M | $46.9M | $86.7M | $50.8M | $12.3M | $52.3M | $43.1M |
| Net Debt | -$21.3M | $142.1M | -$340.7M | -$2.21B | -$1.41B | -$854.7M | -$602.8M | -$467.5M | -$438.2M |
| Working Capital | $220.9M | $8.3M | $542.3M | $2.28B | $1.45B | $847.3M | $620.7M | $510.3M | $491.9M |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 3.05 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -5.79 |
Profitability
| Return on Equity | -10.96% |
| Return on Invested Capital | -10.10% |
| Return on Assets | -7.53% |
| Gross Margin | 74.55% |
| Operating Margin | -11.37% |
| Net Margin | -11.53% |
Related companies: ADVB · AEMD · ALUR · AMS · AYTU · CODX · EKSO
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BNR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks